{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.70","value":"163.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"}],"units":"Participants"}],"title":"HuMax-TF (C1D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.02","value":"41691.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"}],"units":"Participants"}],"title":"HuMax-TF (C1D1-end of infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"150.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"HuMax-TF (C6D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.88","value":"36941"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"HuMax-TF (C6D1-end of infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"30.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"HuMax-TF-ADC (C1D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.62","value":"38105"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"HuMax-TF-ADC (C1D1-end of infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"30.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"HuMax-TF-ADC (C6D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.29","value":"36270.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"HuMax-TF-ADC (C6D1-end of infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"12.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"title":"MMAE (C1D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"102.05","value":"171.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"MMAE (C1D1-end of infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"146.11","value":"46.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"MMAE (C6D1-predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.62","value":"177.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"MMAE (C6D1-end of infusion)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"description":"Plasma concentrations of HuMax-TF, HuMax-TF-ADC, and Free MMAE measures on Cycle 1 Day 1 (predose and end of infusion) and Cycle 6 Day 1 (predose and end of infusion) are reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"FAS included all participants who received at least 1 dose of tisotumab vedotin.","reportingStatus":"POSTED","timeFrame":"Predose and end of infusion of Cycle 1 Day 1 (C1D1) and Cycle 6 Day 1 (C6D1)","title":"Plasma Concentrations of Tisotumab Vedotin (HuMax-TF), Tisotumab Vedotin Antibody-drug Conjugate (HuMax-TF-ADC), and Free Monomethyl Auristatin E (MMAE)","type":"SECONDARY","unitOfMeasure":"ng/mL"}